Compare

Krystal Biotech/$KRYS

1D1W1M3M6MYTD1Y5YMAX

About Krystal Biotech

Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Ticker
$KRYS
Sector
Health
Primary listing
NASDAQ
Employees
295

Krystal Biotech Metrics

BasicAdvanced
$8.8B
40.47
$7.36
0.65
-

What the Analysts think about Krystal Biotech

Analyst ratings (Buy, Hold, Sell) for Krystal Biotech stock.
Analyst projections of the future price of Krystal Biotech stock.

Bulls say / Bears say

VYJUVEK generated $127.3 million in global revenue in Q3, up 30% year on year, with a 94% gross margin. More than 760 US reimbursement approvals and growing launches abroad provide room for further growth. (Krystal Biotech)
Krystal reported $1.2 billion in cash and investments and $63.1 million in Q3 net income, giving it substantial capacity to fund development and expansion. Its planned $400 million share repurchase also signals management confidence in the business. (Krystal Biotech)
Early KB113 results showed regression in more than 80% of assessed lesions across three patients with Gorlin syndrome, including lesions that were not injected. If confirmed in larger studies, this could broaden Krystal’s opportunity beyond its lead product. (Krystal Biotech)
US VYJUVEK sales have been hovering around $85 million to $95 million per quarter and fell 4.6% year on year in Q2, making overseas growth increasingly important. That leaves the company exposed if domestic demand stalls before other products contribute. (Seeking Alpha, Investing.com)
International growth faces uneven access and pricing timelines: European and Japanese revenue was broadly flat in Q2 after a German pricing reserve, and French pricing discussions are not expected to conclude before 2027. These delays could defer the payoff from overseas launches. (Stock Analysis, Krystal Biotech)
Pipeline diversification is taking longer than expected. Slower enrolment pushes KB801 top-line results into 2027, while interim results for KB407 are now expected in the first half of 2027. (Krystal Biotech)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2026.

Krystal Biotech Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

Krystal Biotech Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.